CD274 and neoplasm: In a multivariate analysis which adjusted for doses of nivolumab received, tumor PD-L1 level and baseline lactate dehydrogenase levels, ORR was significantly better in patients who experienced any-grade IRAEs than those who did not experience them (48.6% vs 17.8%, p < .001).